MannKind announces 17-week results from INHALE-3 study

MannKind announced 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza vs. usual care utilizing a higher initial conversion dose from mealtime injectable insulin to inhaled insulin. The study, which was presented by the INHALE-3 investigational team at the American Diabetes Association’s 84th Scientific Sessions in Orlando, met its primary efficacy endpoint of a non-inferior change in HbA1c between baseline and week 17 compared to the usual care group. “INHALE-3 adds to the body of evidence that when combined with basal insulin, inhaled insulin’s effect on HbA1c/TIR is similar to that of the usual care (inclusive of AID pumps) with no new safety concerns,” said Kevin Kaiserman, Senior Vice President, Clinical Development and Medical Affairs for MannKind Corporation. “Our data continues to show the importance of Afrezza as a safe and effective tool for managing diabetes.”